Strategic Collaboration Upgraded: Novartis China and Shanghai Pharma Launch Cardiovascular Health Management Center to Redefine Pharmacy-Based Patient Care

May 26, 2025 22:21 CST Updated 22:21

Novartis China

Innovative Drug Developer

Shanghai Pharma

Modern Pharmaceutical Supply Chain Service Provider

SPH Health Commerce

Prescription Drug New Retail "Internet+" Development Platform Provider

On May 26, 2025, Novartis China, Shanghai Pharmaceutical Co., Ltd., and SPH Health Commerce jointly created the first batch in China"Cardiovascular Health Management Center" Officially Launched at "SPH Health Commerce·Comprehensive Flagship Complex"Embarking on a New Journey of Strategic Upgrade for Novartis China and Shanghai Pharmaceutical Co., Ltd.

The launch ceremony was graced by six leaders who performed the ribbon-cutting: Yao Li, President and Managing Director of Novartis China; Hui Chen, Head of Retail, Emerging Markets, and Commerce at Novartis China; Junxing Wang, Head of Retail at Novartis China; Yongzhong Li, Executive Director and Executive President of Shanghai Pharma; Zhigang Li, Retail Business Director of Shanghai Pharmaceutical Co., Ltd. and Chairman of SPH Health Commerce; and Yeli Qian, CEO of SPH Health Commerce. Together, they witnessed this milestone moment, marking the convergence of multiple forces to initiate an innovative ecosystem of industry collaboration.

Novartis China will partner with Shanghai Pharmaceutical Co., Ltd. and SPH Health Commerce to build a patient-centered cardiovascular disease management platform.Integrate medical resources within and outside the hospital to create a standardized diagnosis and treatment process for hyperlipidemia, combine the unique advantages of SPH Health Commerce, and utilize AI technology and the Internet hospital platform.Jointly create a new ecosystem for value pharmacies and specialized disease patient health services, "Yi" ushers in a new chapter of value retail.

Leo Li, President and Managing Director of Novartis China, stated that as a globally leading innovative pharmaceutical company, Novartis has always adhered to the concept of "Commitment to China," dedicating itself to envisioning the future of medicine, improving people's quality of life, and extending human lifespan. The off-hospital retail channel is an important component of China's innovative drug ecosystem, and Novartis continues to deepen its close collaboration with all parties in China's pharmaceutical retail sector.As we further upgrade our collaboration with Shanghai Pharmaceutical Co., Ltd. and SPH Health Commerce, we hope to leverage Novartis’ innovative product pipeline and integrate the resources and strengths of Shanghai Pharma to deepen our cooperation in enhancing the accessibility of innovative drugs and building smart retail scenarios.Continuously benefit more patients and truly help improve the health level of the Chinese people.

Li Yongzhong, Executive Director and Executive President of Shanghai Pharmaceutical Co., Ltd., first expressed gratitude to Novartis for its long-term support and trust in Shanghai Pharma Health Commerce. He stated,For many years, Shanghai Pharmaceutical Co., Ltd. has maintained a good cooperative relationship with Novartis China. Today, the strategic cooperation between the two parties has been significantly upgraded. Shanghai Pharmaceutical will continue to leverage its advantages in the supply chain network and innovative ecosystem to accelerate the expansion of the coverage and accessibility of more innovative products from Novartis China in the Chinese market.Looking forward to both parties working together to explore new approaches based on the characteristics of patients' diseases and their medication journeys, continuously creating a closed-loop service in professional out-of-hospital scenarios, bringing the management model for cardiovascular disease patients into a more professional new era, and embarking on a value leap in pharmaceutical new retail.

For patients with cardiovascular diseases, after receiving standardized diagnosis and treatment in the hospital, continuous medication management and health guidance become key links to prolong treatment adherence.As one of the important disease management centers of "SPH Health Commerce Comprehensive Flagship System", the newly launched "Cardiovascular Health Management Center" marks a significant expansion of specialized disease management service scenarios.Centered on patients with cardiovascular diseases, this center deeply integrates Novartis' global innovative drugs, Shanghai Pharmaceutical's supply chain resources, and SPH Health Commerce’s professional and digital intelligent capabilities. Throughout the entire journey of patients—from pre-consultation, post-treatment, to follow-up medication—a specialized team of pharmacists is in place to provide personalized medication guidance, indicator tracking, and follow-up visit support. Relying on deep collaboration with core medical institutions, this center builds four comprehensive service loops covering infusion services, medication follow-ups, revisit consultations, and ongoing follow-ups, ensuring precise implementation of treatment plans and long-term adherence. It establishes a one-stop off-hospital health management platform that combines all-around care, professionalism, and privacy protection.

At the same time, the "Cardiovascular Health Management Center," as a specialized innovative scenario within the value pharmacy system co-built by Shanghai Pharmaceutical Co., Ltd., SPH Health Commerce, and Novartis China, is underpinned by the logic of enhancing patient experience and long-term benefits through in-depth single-disease management, thereby reshaping the value of professional pharmacies.The current system has covered disease areas such as dermatology, breast cancer, hyperlipidemia, and hypertension. Through the "software and hardware upgrades - disease zone construction - pharmacist capability development"三位一体 construction, pharmacies are upgraded into comprehensive, full-cycle, diversified service terminals.Both parties will focus on the upgrading of professional services in single-disease management, promoting the essential transformation of the pharmaceutical retail industry from a sales transaction venue to a health management hub.

Against the backdrop of the in-depth advancement of the "Healthy China 2030" strategy, the pharmaceutical industry is undergoing a transformative shift from "disease treatment-centered" to "health management-centered." This innovative flagship, setting sail towards the "new retail blue ocean," starts with out-of-hospital specialized disease management services. Through multi-channel, multi-scenario, and comprehensive approaches, it provides full-course disease management services for patients. By breaking conventional thinking and embracing innovation, it creates strong support for the new health industry, working together with the industry to build and share a Healthy China.